Search

Displaying results 991 - 1000 of 7644 in total
  1. Drug

    Bimekizumab

    go.drugbank.com/drugs/DB12917
    ApprovedInvestigational

    of moderate-to-severe psoriasis,[A244450,A244455] likely owing to its dual inhibition of both IL-17A and IL-17F. … Bimekizumab was also granted FDA approval on October 18, 2023.[L48551]

  2. Drug

    Histidine

    go.drugbank.com/drugs/DB00117
    ApprovedInvestigationalNutraceutical

    An essential amino acid that is required for the production of histamine.

    Mixtures: PF K-CAMINE %8 AMINO ASIT IV INFUZYON ICIN COZELTI, 500 ML (SETLI), PF K-CAMINE %8 AMINO ASIT IV INFUZYON ICIN COZELTI, 1000 ML (SETLI)
  3. Drug

    Hydroxypropyl cellulose

    go.drugbank.com/drugs/DB00840
    Approved

    It is used to treat syndromes characterized by insufficient tear production (keratoconjunctivitis sicca), recurrent corneal erosions, decreased corneal sensitivity, exposure and neuroparalytic keratitis

  4. Drug

    Quercus nigra pollen

    go.drugbank.com/drugs/DB10742
    Approved

    Quercus nigra pollen is the pollen of the Quercus nigra plant. Quercus nigra pollen is mainly used in allergenic testing.

    Mixtures: 5-oak Mix, Blackjack/bur/post/red/white PollenCategories: Non-Standardized Pollen Allergenic Extract
  5. Drug

    Rotigotine

    go.drugbank.com/drugs/DB05271
    ApprovedInvestigational

    It was approved by the European Medicines Agency in 2006 and by the FDA in 2007. … Rotigotine was developed by Aderis Pharmaceuticals. In 1998 Aderis licensed worldwide development and commercialization rights to Schwarz Pharma of Germany.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  6. Drug

    Betahistine

    go.drugbank.com/drugs/DB06698
    ApprovedInvestigational

    [A220333,L16403] Betahistine was first approved by the FDA in the 1970s but withdrawn within approximately 5 years due to a lack of evidence supporting its efficacy. … It is currently marketed in Canada by various companies, including Teva Pharmaceuticals.

    Synonyms: N-methyl-2-pyridineethanamine, N-methyl-2-(2-pyridinyl)ethanamineProducts: BETAVERT N 8MG, BETAVERT N 16MG
  7. Drug

    Sodium acetate

    go.drugbank.com/drugs/DB09395
    ApprovedInvestigational

    It is mainly indicated to correct sodium levels in hyponatremic patients. It can be used also in metabolic acidosis and for urine alkalinization.

    Mixtures: OLICLINOMEL N4-550 E EMULSION FOR INFUSION, OLICLINOMEL N7-1000 E EMULSION FOR INFUSION
  8. Drug

    Foreskin fibroblast (neonatal)

    go.drugbank.com/drugs/DB10770
    Approved

    Interestingly, it has been shown that human foreskin cells possess immunosuppressive properties, which are mediated by other processes than that reported for bone marrow/stromal stem cells [A32655]. … Dermagraft has been combined with [DB10772] to create a drug beneficial to patients with open burn wounds [L2427].

  9. Drug

    Lodoxamide

    go.drugbank.com/drugs/DB06794
    Approved

    Lodoxamide is marketed under the brand name Alomide by Alcon.

    Synonyms: N,N'-(2-chloro-5-cyano-m-phenylene)dioxamate
  10. Drug

    Sacituzumab govitecan

    go.drugbank.com/drugs/DB12893
    ApprovedInvestigational

    [L13002, A193674] Sacituzumab govitecan was granted FDA approval on April 22nd, 2020 and is marketed under the brand name Trodelvy™ by Immunomedics, Inc.; it is currently indicated under accelerated … [A193653] In November 2021 and July 20 2023, sacituzumab govitecan was also approved by the European Commission and Health Canada respectively.[L39372,L47601]